Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Cell
Adam C Palmer, Peter K Sorger

Abstract

Combination cancer therapies aim to improve the probability and magnitude of therapeutic responses and reduce the likelihood of acquired resistance in an individual patient. However, drugs are tested in clinical trials on genetically diverse patient populations. We show here that patient-to-patient variability and independent drug action are sufficient to explain the superiority of many FDA-approved drug combinations in the absence of drug synergy or additivity. This is also true for combinations tested in patient-derived tumor xenografts. In a combination exhibiting independent drug action, each patient benefits solely from the drug to which his or her tumor is most sensitive, with no added benefit from other drugs. Even when drug combinations exhibit additivity or synergy in pre-clinical models, patient-to-patient variability and low cross-resistance make independent action the dominant mechanism in clinical populations. This insight represents a different way to interpret trial data and a different way to design combination therapies.

Citations

Mar 3, 2018·Journal of Clinical Medicine·Juliet A Williams
May 8, 2018·Bulletin of Mathematical Biology·Nara YoonJacob G Scott
May 24, 2018·The FEBS Journal·Annika HantuschThomas Brunner
Oct 29, 2018·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Shahla ShojaeiSaeid Ghavami
Oct 31, 2018·Seminars in Immunopathology·Emmett V Schmidt
Sep 28, 2018·Annual Review of Pharmacology and Toxicology·J G Coen van Hasselt, Ravi Iyengar
Mar 5, 2019·PLoS Computational Biology·Thomas DupicThierry Mora
Apr 13, 2019·Journal of Cellular Biochemistry·Yuzhen ZhouYan Huang
Apr 23, 2019·PLoS Computational Biology·András SzabóRoberto Mayor
Mar 27, 2019·Clinical Pharmacology and Therapeutics·Jin NiuDonald E Mager
Jun 13, 2019·Natural Product Reports·Lindsay K Caesar, Nadja B Cech
Nov 15, 2019·PloS One·Viktor SandblomEva Forssell-Aronsson
Nov 8, 2019·Blood·David M Weinstock, Steven M Horwitz
Feb 23, 2020·PLoS Computational Biology·Natacha Comandante-LouMohammad Fallahi-Sichani
Feb 29, 2020·Antioxidants·Emiliano PanieriLuciano Saso
May 5, 2020·PLoS Computational Biology·Tal Einav, Jesse D Bloom
Sep 10, 2019·PLoS Computational Biology·Yin ZhangTongli Zhang
Apr 7, 2020·Nature Chemical Biology·Ryan RichardsMichael J Lee
May 22, 2020·Expert Review of Anticancer Therapy·Qian QinMatthew D Galsky
Jul 18, 2019·NPJ Systems Biology and Applications·Jing TangTero Aittokallio
Jun 20, 2020·Clinical Pharmacology and Therapeutics·Sebastien Benzekry
Oct 12, 2019·NPJ Systems Biology and Applications·Nirmal KeshavaDennis Wang
Jan 11, 2019·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Seung Tack OhBoo Ahn Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.